Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. - Ding, Lu; Nuersulitan, Reyizha; Wang, Jingjing; Chen, Hanxiao; Zhuo, Minglei (Current Oncology, 2026)